Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working GroupAntonio Palumbo, Philippe Moreau, Brian G.M. Durie et al.|Journal of Clinical Oncology|2015Cited by 2.2k
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple MyelomaDavid H. Henry, Howard Yeh, Luís Costa et al.|Journal of Clinical Oncology|2011Cited by 1.3k
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple MyelomaJesús F. San Miguel, Hermann Einsele, Binod Dhakal et al.|New England Journal of Medicine|2023Cited by 719
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 studyMichel Attal, Michel Pavic, Paul G. Richardson et al.|The Lancet|2019Cited by 635
International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell TransplantationAntonio Palumbo, Robert Z. Orlowski, S. Vincent Rajkumar et al.|Journal of Clinical Oncology|2014Cited by 384